IL155178A0 - Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation - Google Patents

Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation

Info

Publication number
IL155178A0
IL155178A0 IL15517801A IL15517801A IL155178A0 IL 155178 A0 IL155178 A0 IL 155178A0 IL 15517801 A IL15517801 A IL 15517801A IL 15517801 A IL15517801 A IL 15517801A IL 155178 A0 IL155178 A0 IL 155178A0
Authority
IL
Israel
Prior art keywords
mutants
preparation
multiple sclerosis
chemokine
new
Prior art date
Application number
IL15517801A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL155178A0 publication Critical patent/IL155178A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15517801A 2000-10-04 2001-10-03 Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation IL155178A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (fr) 2000-10-04 2001-10-03 Mutants de chimiokines intervenant dans le traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
IL155178A0 true IL155178A0 (en) 2003-11-23

Family

ID=8170011

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15517801A IL155178A0 (en) 2000-10-04 2001-10-03 Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation
IL155178A IL155178A (en) 2000-10-04 2003-04-01 Use of Kamokin mutants to prepare a drug for the treatment of multiple sclerosis, such new mutants and their preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155178A IL155178A (en) 2000-10-04 2003-04-01 Use of Kamokin mutants to prepare a drug for the treatment of multiple sclerosis, such new mutants and their preparation

Country Status (31)

Country Link
US (1) US7402303B2 (fr)
EP (1) EP1326628B1 (fr)
JP (1) JP3908165B2 (fr)
KR (1) KR100837898B1 (fr)
CN (1) CN1285381C (fr)
AR (1) AR030854A1 (fr)
AT (1) ATE265222T1 (fr)
AU (2) AU1591902A (fr)
BG (1) BG66137B1 (fr)
BR (1) BR0114407A (fr)
CA (1) CA2423616C (fr)
CZ (1) CZ303409B6 (fr)
DE (1) DE60103078T2 (fr)
DK (1) DK1326628T3 (fr)
EA (1) EA006137B1 (fr)
EE (1) EE05174B1 (fr)
ES (1) ES2217199T3 (fr)
HK (1) HK1062811A1 (fr)
HR (1) HRP20030215B1 (fr)
HU (1) HUP0302194A3 (fr)
IL (2) IL155178A0 (fr)
MX (1) MXPA03003008A (fr)
NO (1) NO330278B1 (fr)
PL (1) PL204231B1 (fr)
PT (1) PT1326628E (fr)
RS (1) RS50738B (fr)
SI (1) SI1326628T1 (fr)
SK (1) SK287523B6 (fr)
UA (1) UA77950C2 (fr)
WO (1) WO2002028419A2 (fr)
ZA (1) ZA200302315B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231057D1 (de) 2001-12-17 2009-03-19 Serono Lab Chemokine mutanten, die als chemokine antagonisten wirken
DK1494703T3 (da) 2002-04-04 2006-06-26 Applied Research Systems Chemokin-mutanter med forbedret oral biotilgængelighed
WO2004062688A2 (fr) * 2002-12-23 2004-07-29 Applied Research Systems Ars Holding N.V. Mutants de la cc-chimiokine contre les maladies du foie
CA2534828A1 (fr) * 2003-10-22 2005-05-06 Applied Research Systems Ars Holding N.V. Nouveaux antagonistes de la cxcl8
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
SI1439191T1 (sl) * 2004-01-19 2006-06-30 Ares Trading Sa Postopek ciscenja proteinov izrazenih v bakteriji
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (fr) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Composé polybenzoxazine, membrane électrolyte contenant ce composé et cellule de combustion employant ce membrane électrolyte
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
DK2185719T3 (en) 2007-08-02 2014-02-17 Novimmune Sa ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
AU2011213559B2 (en) * 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
CN112469430A (zh) 2018-05-28 2021-03-09 日内瓦大学 抑制大脑炎症的方法
WO2022093857A1 (fr) * 2020-10-26 2022-05-05 City Of Hope Compositions de virus oncolytiques et méthodes de traitement du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (fr) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Antagonistes des recepteurs de mcp-3, rantes et mip-1alpha
EP0906954A1 (fr) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. C-C chémokine tronquée à l'aminoterminus comme antagoniste de chémokines
AU2415599A (en) * 1997-12-23 1999-07-19 Fondazione Centro San Raffaele Del Monte Tabor Rantes mutants and therapeutic applications thereof
WO2000044408A2 (fr) * 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1

Also Published As

Publication number Publication date
EP1326628B1 (fr) 2004-04-28
BR0114407A (pt) 2003-07-29
DK1326628T3 (da) 2004-08-09
KR20030034238A (ko) 2003-05-01
CA2423616A1 (fr) 2002-04-11
SK4062003A3 (en) 2003-08-05
HK1062811A1 (en) 2004-11-26
AU2002215919B2 (en) 2005-11-24
ZA200302315B (en) 2004-03-25
RS50738B (sr) 2010-08-31
NO330278B1 (no) 2011-03-21
JP2004510426A (ja) 2004-04-08
ATE265222T1 (de) 2004-05-15
DE60103078D1 (de) 2004-06-03
PT1326628E (pt) 2004-09-30
BG107685A (bg) 2003-11-28
HRP20030215B1 (en) 2011-09-30
NO20031525D0 (no) 2003-04-03
EE200300139A (et) 2003-06-16
SK287523B6 (sk) 2011-01-04
ES2217199T3 (es) 2004-11-01
MXPA03003008A (es) 2003-07-14
YU25703A (sh) 2006-05-25
HUP0302194A2 (hu) 2003-10-28
NO20031525L (no) 2003-04-03
IL155178A (en) 2009-07-20
WO2002028419A2 (fr) 2002-04-11
CN1477969A (zh) 2004-02-25
AR030854A1 (es) 2003-09-03
CA2423616C (fr) 2010-03-16
PL362350A1 (en) 2004-10-18
UA77950C2 (en) 2007-02-15
AU1591902A (en) 2002-04-15
US7402303B2 (en) 2008-07-22
EE05174B1 (et) 2009-06-15
CN1285381C (zh) 2006-11-22
EA006137B1 (ru) 2005-10-27
CZ2003947A3 (cs) 2003-11-12
EA200300439A1 (ru) 2003-08-28
WO2002028419A3 (fr) 2002-06-13
PL204231B1 (pl) 2009-12-31
BG66137B1 (bg) 2011-07-29
HUP0302194A3 (en) 2005-12-28
HRP20030215A2 (en) 2005-02-28
SI1326628T1 (en) 2004-10-31
KR100837898B1 (ko) 2008-06-13
EP1326628A2 (fr) 2003-07-16
JP3908165B2 (ja) 2007-04-25
DE60103078T2 (de) 2005-04-07
US20040101509A1 (en) 2004-05-27
CZ303409B6 (cs) 2012-09-05

Similar Documents

Publication Publication Date Title
HUP0301417A2 (hu) Antimikrobális és fogamzásgátló készítmények és alkalmazásuk
IL155178A0 (en) Use of chemokine mutants in multiple sclerosis, some such new mutants and their preparation
ZA978089B (en) 3,4-diaryloxazolone derivatives, their methods of preparation, and their use in therapeutics.
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU4209301A (en) Chair and table assembly
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
HK1072948A1 (en) Ifnar2 mutants, their production and use
HUP0303936A3 (en) Novel composition and use
AU2001236001A1 (en) Immune enhancement compositions and use thereof
AU5104101A (en) Composition and use
AU2001269106A1 (en) Novel alpha expressed in heart and testis
IL146940A0 (en) Novel calpains and their use
GB0014191D0 (en) Use and combined preparation
GB0106809D0 (en) Organomagnesium fluorides and preparation of
AU5025801A (en) Novel polypeptide---a human hexose kinase 13 and polynucleotide encoding it
AU2002212046A1 (en) Novel polypeptide--- the human cytokine receptor 13.31 and polynucleotide encoding it
SI1379639T1 (sl) Misja glukoronil C5-epimeraza, DNA, ki kodira le-to, in njena uporaba
GB0002560D0 (en) Virulence gene and protein and their use
GB0003727D0 (en) Virulence gene and protein and their use
GB0002558D0 (en) Virulence gene and protein and their use
GB0002561D0 (en) Virulence gene and protein and their use
GB0003726D0 (en) Virulence gene and protein and their use
GB0002564D0 (en) Virulence gene and protein and their use
GB0003725D0 (en) Virulence gene and protein and their use